Synthetic nucleic acids and treatment of neurological diseases

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Importance The ability to control gene expression with antisense oligonucleotides (ASOs) could provide a new treatment strategy for disease. OBJECTIVE To review the use of ASOs for the treatment of neurological disorders. EVIDENCE REVIEW Articles were identified through a search of PubMed references from 2000 to 2016 for articles describing the use of ASOs to treat disease, with specific attention to neurological disease. We concentrated our review on articles pertaining to activation of frataxin expression (Friedreich's ataxia) and production of active survival motor neuron 2 (SMN2, spinal muscular atrophy). FINDINGS Many neurological diseases are caused by inappropriate expression of a protein. Mutations may reduce expression of a wild-type protein, and strategies to activate expression may provide therapeutic benefit. For other diseases, a mutant protein may be expressed too highly and methods that reduce mutant protein expression might form the basis for drug development. Synthetic ASOs can recognize cellular RNA and control gene expression. Antisense oligonucleotides are not a new concept, but successful clinical development has proceeded at a slow pace. Advances in ASO chemistry, biological understanding, and clinical design are making successful applications more likely. CONCLUSIONS AND RELEVANCE Both laboratory and clinical studies are demonstrating the potential of ASOs as a source of drugs to treat neurological disease.

Original languageEnglish (US)
Pages (from-to)1238-1242
Number of pages5
JournalJAMA Neurology
Volume73
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Antisense Oligonucleotides
Nucleic Acids
Mutant Proteins
Friedreich Ataxia
Gene Expression
Spinal Muscular Atrophy
Motor Neurons
Nervous System Diseases
PubMed
Pharmaceutical Preparations
Proteins
RNA
Mutation

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Synthetic nucleic acids and treatment of neurological diseases. / Corey, David R.

In: JAMA Neurology, Vol. 73, No. 10, 01.10.2016, p. 1238-1242.

Research output: Contribution to journalReview article

@article{640c6c01964e435cb6d5df4a17fb34b0,
title = "Synthetic nucleic acids and treatment of neurological diseases",
abstract = "Importance The ability to control gene expression with antisense oligonucleotides (ASOs) could provide a new treatment strategy for disease. OBJECTIVE To review the use of ASOs for the treatment of neurological disorders. EVIDENCE REVIEW Articles were identified through a search of PubMed references from 2000 to 2016 for articles describing the use of ASOs to treat disease, with specific attention to neurological disease. We concentrated our review on articles pertaining to activation of frataxin expression (Friedreich's ataxia) and production of active survival motor neuron 2 (SMN2, spinal muscular atrophy). FINDINGS Many neurological diseases are caused by inappropriate expression of a protein. Mutations may reduce expression of a wild-type protein, and strategies to activate expression may provide therapeutic benefit. For other diseases, a mutant protein may be expressed too highly and methods that reduce mutant protein expression might form the basis for drug development. Synthetic ASOs can recognize cellular RNA and control gene expression. Antisense oligonucleotides are not a new concept, but successful clinical development has proceeded at a slow pace. Advances in ASO chemistry, biological understanding, and clinical design are making successful applications more likely. CONCLUSIONS AND RELEVANCE Both laboratory and clinical studies are demonstrating the potential of ASOs as a source of drugs to treat neurological disease.",
author = "Corey, {David R.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1001/jamaneurol.2016.2089",
language = "English (US)",
volume = "73",
pages = "1238--1242",
journal = "JAMA Neurology",
issn = "2168-6149",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Synthetic nucleic acids and treatment of neurological diseases

AU - Corey, David R.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Importance The ability to control gene expression with antisense oligonucleotides (ASOs) could provide a new treatment strategy for disease. OBJECTIVE To review the use of ASOs for the treatment of neurological disorders. EVIDENCE REVIEW Articles were identified through a search of PubMed references from 2000 to 2016 for articles describing the use of ASOs to treat disease, with specific attention to neurological disease. We concentrated our review on articles pertaining to activation of frataxin expression (Friedreich's ataxia) and production of active survival motor neuron 2 (SMN2, spinal muscular atrophy). FINDINGS Many neurological diseases are caused by inappropriate expression of a protein. Mutations may reduce expression of a wild-type protein, and strategies to activate expression may provide therapeutic benefit. For other diseases, a mutant protein may be expressed too highly and methods that reduce mutant protein expression might form the basis for drug development. Synthetic ASOs can recognize cellular RNA and control gene expression. Antisense oligonucleotides are not a new concept, but successful clinical development has proceeded at a slow pace. Advances in ASO chemistry, biological understanding, and clinical design are making successful applications more likely. CONCLUSIONS AND RELEVANCE Both laboratory and clinical studies are demonstrating the potential of ASOs as a source of drugs to treat neurological disease.

AB - Importance The ability to control gene expression with antisense oligonucleotides (ASOs) could provide a new treatment strategy for disease. OBJECTIVE To review the use of ASOs for the treatment of neurological disorders. EVIDENCE REVIEW Articles were identified through a search of PubMed references from 2000 to 2016 for articles describing the use of ASOs to treat disease, with specific attention to neurological disease. We concentrated our review on articles pertaining to activation of frataxin expression (Friedreich's ataxia) and production of active survival motor neuron 2 (SMN2, spinal muscular atrophy). FINDINGS Many neurological diseases are caused by inappropriate expression of a protein. Mutations may reduce expression of a wild-type protein, and strategies to activate expression may provide therapeutic benefit. For other diseases, a mutant protein may be expressed too highly and methods that reduce mutant protein expression might form the basis for drug development. Synthetic ASOs can recognize cellular RNA and control gene expression. Antisense oligonucleotides are not a new concept, but successful clinical development has proceeded at a slow pace. Advances in ASO chemistry, biological understanding, and clinical design are making successful applications more likely. CONCLUSIONS AND RELEVANCE Both laboratory and clinical studies are demonstrating the potential of ASOs as a source of drugs to treat neurological disease.

UR - http://www.scopus.com/inward/record.url?scp=84999026149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84999026149&partnerID=8YFLogxK

U2 - 10.1001/jamaneurol.2016.2089

DO - 10.1001/jamaneurol.2016.2089

M3 - Review article

C2 - 27479447

AN - SCOPUS:84999026149

VL - 73

SP - 1238

EP - 1242

JO - JAMA Neurology

JF - JAMA Neurology

SN - 2168-6149

IS - 10

ER -